In an attempt to diversify its pipeline, Boehringer Ingelheim has signed a strategic collaboration and licensing agreement, worth up to €755 M (US$825.96 M), to access Sosei’s G protein-coupled receptor (GPCR) agonist, HTL0048149. This candidate has the potential to address the unmet needs of patients who do not respond to existing treatments of schizophrenia. The deal combines Sosei's cutting-edge technology-based asset with Boehringer’s commercialisation expertise and global distribution network.